Crossmark Global Holdings Inc. Acquires 449 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Crossmark Global Holdings Inc. raised its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 25.8% during the third quarter, HoldingsChannel reports. The firm owned 2,186 shares of the company’s stock after purchasing an additional 449 shares during the period. Crossmark Global Holdings Inc.’s holdings in Krystal Biotech were worth $398,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the business. Sei Investments Co. increased its holdings in Krystal Biotech by 128.3% during the first quarter. Sei Investments Co. now owns 33,752 shares of the company’s stock valued at $6,005,000 after buying an additional 18,968 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in shares of Krystal Biotech by 54.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 658,618 shares of the company’s stock valued at $117,189,000 after acquiring an additional 231,255 shares during the period. Shaker Investments LLC OH bought a new position in shares of Krystal Biotech in the 3rd quarter worth $532,000. Amalgamated Bank lifted its stake in shares of Krystal Biotech by 937.9% during the 2nd quarter. Amalgamated Bank now owns 7,577 shares of the company’s stock worth $1,391,000 after purchasing an additional 6,847 shares during the last quarter. Finally, Everence Capital Management Inc. bought a new stake in Krystal Biotech during the third quarter valued at about $557,000. Institutional investors own 86.29% of the company’s stock.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the sale, the insider now directly owns 1,500,882 shares of the company’s stock, valued at approximately $296,814,424.32. This trade represents a 1.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 14.10% of the stock is owned by insiders.

Krystal Biotech Trading Down 3.7 %

NASDAQ:KRYS opened at $170.74 on Monday. The company has a market capitalization of $4.91 billion, a P/E ratio of 96.46 and a beta of 0.82. Krystal Biotech, Inc. has a 12 month low of $96.73 and a 12 month high of $219.34. The firm has a fifty day simple moving average of $180.83 and a 200-day simple moving average of $181.64.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.84 by $0.07. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The company had revenue of $83.84 million during the quarter, compared to analysts’ expectations of $82.94 million. During the same quarter in the previous year, the firm posted ($0.67) EPS. The firm’s revenue was up 879.9% compared to the same quarter last year. Equities analysts forecast that Krystal Biotech, Inc. will post 2.97 EPS for the current year.

Analyst Ratings Changes

Several research firms have commented on KRYS. William Blair raised shares of Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. Stifel Nicolaus raised their target price on shares of Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a research note on Wednesday, September 11th. Evercore ISI lifted their price target on shares of Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a report on Monday, August 12th. Chardan Capital increased their price objective on Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a report on Monday, August 5th. Finally, HC Wainwright restated a “buy” rating and set a $221.00 target price on shares of Krystal Biotech in a research note on Tuesday, November 5th. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $197.00.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).